Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.

Enrico de NigrisCatrin TreharneNick BrightonUlf HolmgrenAndrew WalkerJohn Haughney

Published in: International journal of chronic obstructive pulmonary disease (2022)

Based on ETHOS data, BGF was demonstrated to be cost-effective versus LAMA/LABA and ICS/LABA dual therapies at the conventional UK-adopted willingness-to-pay threshold (ICUR <£20,000). The main cost-effectiveness driver for BGF versus LAMA/LABA and ICS/LABA therapies was reduction in rate of exacerbations, which reduced costs and preserved quality of life.

Keyphrases

chronic obstructive pulmonary disease
muscular dystrophy
electronic health record
early onset
lung function
stem cells
machine learning
bone marrow
big data
health insurance
mesenchymal stem cells
air pollution
cell therapy